about
Hormonal contraceptives: pharmacology tailored to women's healthDrospirenone and its antialdosterone propertiesEfficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne.Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorderProgestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effectsNew progestagens for contraceptive use.Androgens and adipose tissue in males: a complex and reciprocal interplay.Role of progestins with partial antiandrogenic effects.Pharmacology of different progestogens: the special case of drospirenone.Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension.Does hormonal contraception prior to in vitro fertilization (IVF) negatively affect oocyte yields? A pilot study.Drospirenone: a novel progestin.Preclinical and clinical properties of trimegestone: a potent and selective progestin.Protective cardiovascular and renal actions of vitamin D and estrogenA review of the cardiovascular and breast actions of drospirenone in preclinical studies.Hypertension in women: the role of progesterone and aldosterone.Construction of spirolactones with concomitant formation of the fused quaternary centre--application to the synthesis of natural products.Contraceptives with novel benefits.Beyaz®: an oral contraceptive fortified with folate.The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.Combination of drospirenone and estradiol: a new hormone therapy in postmenopausal women.Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations.Cycle-Related Changes in Mood, Sexual Desire, and Sexual Activity in Oral Contraception-Using and Nonhormonal-Contraception-Using Couples.A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.
P2860
Q26745814-6500E9B2-38EA-4010-950C-84D418541064Q28293272-D9E7FAD3-2E4B-4E3B-8D3D-8AEBDD92B068Q34271948-9378F244-73A2-4820-AD3B-42D1808FD84AQ34272049-729422DF-15A9-4791-A5C8-F69954E578DAQ34317537-4E2E2622-7DCB-4EBA-9476-7CA31E1E9C90Q34468158-B34D2808-CBC7-4F1C-8C52-EA2AC19547EBQ35659922-761E2FA0-A0F4-46C6-83F0-1D6CC9F5ED9BQ36019567-15DDA6B2-4613-4F5C-AC7C-ABF7C14CA611Q36276322-FA4E7C03-B713-44EE-81EE-C712F73C11A8Q36761438-84B5E322-AF05-48C2-85D5-4D8CAFCBC03CQ36797854-45F8725B-22F8-4153-BA3B-BFA733BD12F6Q36808051-CF56BA8C-3946-43A2-8881-E7C3221FE4D3Q36872678-35A0B672-8E8A-447A-871B-F4AC7F471E60Q36905627-BEF3254D-21E1-4F43-BEF4-43DCD2AF8B9FQ37638712-BEC296D3-3658-4087-A4F3-9BA5BB51EEEDQ37742631-D3ED9B09-3218-4368-9ECA-1C6C21C8D714Q37835028-248C4F82-51A4-4DED-B22A-F544C77102E2Q37965736-339C5CE3-5BEF-4973-BADE-60FAABCCBC8CQ37968645-FEF77CF6-B9E7-4DA7-83FF-3815F8FB42FCQ38817439-BCE45FEE-C35D-4460-8433-2D682B5D2AEFQ43143216-8016B84D-FB44-4A90-98DB-77BFA35B3AF1Q43267025-46341491-1A51-4E26-AEE8-0FBE8CE63B63Q46145068-E0943723-DC4A-4CF2-B65A-9C1436CEB7FCQ47786132-BD585DF8-B77C-4737-8A15-37121284F7EBQ52865456-39F83865-165A-4278-A499-964879035CE8
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Conception and pharmacodynamic profile of drospirenone
@ast
Conception and pharmacodynamic profile of drospirenone
@en
Conception and pharmacodynamic profile of drospirenone
@nl
type
label
Conception and pharmacodynamic profile of drospirenone
@ast
Conception and pharmacodynamic profile of drospirenone
@en
Conception and pharmacodynamic profile of drospirenone
@nl
prefLabel
Conception and pharmacodynamic profile of drospirenone
@ast
Conception and pharmacodynamic profile of drospirenone
@en
Conception and pharmacodynamic profile of drospirenone
@nl
P2093
P1433
P1476
Conception and pharmacodynamic profile of drospirenone
@en
P2093
Alexander Hillisch
Kunhard Pollow
Robert Garfield
Shao Qing Shi
Sybille Beier
Walter Elger
P304
P356
10.1016/J.STEROIDS.2003.08.008
P407
P577
2003-11-01T00:00:00Z